Samaresh Sau
Impact in
- Biomaterials top 1%
- Nanoparticle-Based Drug Delivery
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Papers in
-
- RNA Interference and Gene Delivery 12
- Biomaterials 28
- Nanoparticle-Based Drug Delivery 28
- Co-authors
- Arun K. Iyer (59 shared papers)Sushil K. Kashaw (20 shared papers)Katyayani Tatiparti (19 shared papers)Hashem O. Alsaab (22 shared papers)Ketki Bhise (15 shared papers)Rami M. Alzhrani (13 shared papers)Prashant Kesharwani (5 shared papers)Rintu Banerjee (6 shared papers)
- Journals
- Drug Discovery Today (10 papers)Cancers (3 papers)Colloids and Surfaces B Biointerfaces (3 papers)Cancer Research (3 papers)Pharmaceutics (2 papers)
- Partner nations
- United StatesIndiaSaudi Arabia
In The Last Decade
Samaresh Sau
68 papers receiving 4.3k citations
Samaresh Sau's Hit Papers
Peers
Comparison fields: 5 of 127
- Biomaterials 963
- Oncology 1.1k
- Pharmaceutical Science 276
- Molecular Medicine 197
- Immunology 742
Countries citing papers authored by Samaresh Sau
This map shows the geographic impact of Samaresh Sau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samaresh Sau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samaresh Sau more than expected).
Fields of papers citing papers by Samaresh Sau
This network shows the impact of papers produced by Samaresh Sau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samaresh Sau. The network helps show where Samaresh Sau may publish in the future.
Co-authors
The 25 scholars most cited alongside Samaresh Sau, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 68 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome Hit paper breakdown → | 2017 | 1314 |
| 2 | 2017 | 350 | |
| 3 | 2017 | 137 | |
| 4 | 2018 | 131 | |
| 5 | 2018 | 125 | |
| 6 | 2017 | 120 | |
| 7 | 2015 | 116 | |
| 8 | 2020 | 106 | |
| 9 | 2021 | 101 | |
| 10 | 2018 | 92 | |
| 11 | 2017 | 89 | |
| 12 | 2017 | 87 | |
| 13 | 2017 | 85 | |
| 14 | 2018 | 82 | |
| 15 | 2019 | 75 | |
| 16 | 2021 | 74 | |
| 17 | 2017 | 67 | |
| 18 | 2018 | 66 | |
| 19 | 2018 | 65 | |
| 20 | 2021 | 58 |
About Samaresh Sau
Samaresh Sau is a scholar working on Molecular Biology, Biomaterials, Biomedical Engineering, Oncology and Immunology, having authored 68 papers that have together received 4.4k indexed citations. Recurring topics across this work include Nanoparticle-Based Drug Delivery (28 papers), Nanoplatforms for cancer theranostics (20 papers), RNA Interference and Gene Delivery (12 papers), Cancer Immunotherapy and Biomarkers (6 papers), Immunotherapy and Immune Responses (5 papers), Graphene and Nanomaterials Applications (5 papers), Advancements in Transdermal Drug Delivery (4 papers) and Curcumin's Biomedical Applications (4 papers). The work is most often cited by research in Biomaterials (963 citations), Oncology (1.1k citations), Pharmaceutical Science (276 citations), Molecular Medicine (197 citations) and Immunology (742 citations). Samaresh Sau has collaborated with scholars based in United States, India and Saudi Arabia. Frequent co-authors include Arun K. Iyer, Sushil K. Kashaw, Katyayani Tatiparti, Hashem O. Alsaab, Ketki Bhise, Rami M. Alzhrani, Prashant Kesharwani, Rintu Banerjee, Lutz Ackermann and Duy Luong. Their work appears in journals such as Drug Discovery Today, Cancers, Colloids and Surfaces B Biointerfaces, Cancer Research and Pharmaceutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.